MedTrace Logo

Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)

NCT01076192 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 547

Last updated 2016-01-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effectiveness and safety of adalimumab as used in routine clinical practice in adult patients with moderate to severe chronic plaque psoriasis in Spain.

Conditions

  • Moderate-to-severe Chronic Plaque Psoriasis

Sponsors & Collaborators

  • IMS Health

    collaborator OTHER

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Cristina Sancho Sanchez, PharmD · Abbvie Farmaceutica, S.L.U. Spain

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2014-09-30
Completion
2014-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01076192 on ClinicalTrials.gov